Newtopia and Eastern Health Improve Outcomes for Individuals Living with Type 2 Diabetes – Yahoo Finance

Abstract presented by Eastern Health at the 2022 Diabetes Canada and Canadian Society of Endocrinology and Metabolism (CSEM) Professional Conference in Calgary.  
TORONTO, Nov. 14, 2022 /CNW/ – Newtopia Inc. (“Newtopia” or the “Company“) (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform creating sustainable habits that prevent, slow and reverse chronic disease, today announced the presentation of the evaluation of outcomes at Canada’s most highly anticipated diabetes-related conference.  The results are from a joint, value-based innovation trial with Eastern Health being tested with the goal to reduce the significant diabetes burden in Newfoundland and Labrador.
The trial itself evolved out of Eastern Health’s recognition of the need to improve health outcomes for approximately 30% of the population – nearly 175,000 Newfoundland and Labrador residents – who live with, or are at risk of, developing diabetes.  Using Newtopia’s personalized lifestyle and habit change platform, participants in the trial in Newfoundland and Labrador received 1:1 dedicated health coaching delivered virtually.
Weight loss trends among participants showed a decrease from baseline of 3.5% of body weight at 6 months and 6.4% at 10 months.  What’s more, among participants with two or more A1c test results, A1c declined by an average of 0.5, and 1.1 for those with an initial A1c of 9.0 or above.  While the trial results are impressive, the engagement levels of 81% among participants, whose average age is 60-years-old, further highlights the successful outcomes that flow from Newtopia’s humans-helping-humans approach amplified by technology. 
“These results are especially encouraging given the number of people in Newfoundland and Labrador who have diabetes,” said Judy O’Keefe, Vice President of Clinical Services, Eastern Health.  “Eastern Health is always interested in innovative products and solutions that have the potential of improving the health of our patients, clients and residents. This trial has shown the success we can have when patients are directly involved in their own care and from the comfort of their own home. It is also an example of the success of providing primary health care that is preventative and patient-centered.”
“As a Canadian-founded health tech leader, we value our collaboration with Eastern Health and are delighted to see Canadians benefiting from our habit change innovation to prevent, reverse and slow chronic disease,” said Jeff Ruby, Founder and CEO of Newtopia. “In addition to the compelling engagement and clinical outcomes, we are pleased to see Eastern Health lead innovation in both slowing and reversing type-2 diabetes and value-based contracting.  We look forward to continuing our relationship with Eastern Health, thereby delivering better diabetes health outcomes to even more of the people of Newfoundland and Labrador, and in time across Canada.” 
These pilot results are also consistent with Newtopia’s recent receipt of the highest Full-Plus recognition from the Centers for Disease Control and Prevention for delivering a proven, highly effective alternative diabetes prevention program.
About Newtopia

Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow, or reverse chronic disease while reducing healthcare costs. The platform leverages genetic, social and behavioral insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed in Canada on the Toronto Stock Exchange (TSXV: NEWU) and is quoted in the US on the OTCQB^® Venture Market (OTCQB: NEWUF). To learn more, visit newtopia.com, LinkedIn or Twitter.
About Eastern Health  
Eastern Health is the largest, integrated health authority in Newfoundland and Labrador employing approximately 13,000 dedicated employees, over 700 medical staff, and is supported by hundreds of volunteers, including members of numerous auxiliaries and fundraising foundations. With an annual budget of approximately $1.7 billion, the authority offers the full continuum of health and community services including public health, long-term care, community services, hospital care and unique provincial programs and services. Serving a population of over 300,000, Eastern Health’s geographic boundaries extend west from St. John’s to Port Blandford including all communities on the Avalon, Burin and Bonavista Peninsulas.
Forward Looking Statements
This news release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable United States securities legislation (collectively, “forward-looking statements”), which reflects management’s expectations regarding Newtopia’s future growth, results from operations (including, without limitation, future production and capital expenditures), performance (both operational and financial) and business prospects and opportunities. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Newtopia’s current views and intentions with respect to future events, based on information available to Newtopia, and are subject to certain risks, uncertainties, and assumptions. Material factors or assumptions were applied in providing forward-looking information. While forward-looking statements are based on data, assumptions and analyses that Newtopia believes are reasonable under the circumstances, whether actual results, performance or developments will meet Newtopia’s expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Forward-looking statements are not a guarantee and are based on a number of estimates and assumptions management believes to be relevant and reasonable, whether actual results, performance or developments will meet Newtopia’s expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Certain of the “risk factors” that could cause actual results to differ materially from Newtopia’s forward-looking statements in this press release include, without limitation: the termination of contracts by clients, risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters- in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; and other general economic, market and business conditions and factors, including the risk factors discussed or referred to in Newtopia’s disclosure documents, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com including Newtopia’s final long form prospectus dated March 30, 2020.
Should any factor affect Newtopia’s in an unexpected manner, or should assumptions underlying the forward- looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Newtopia does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release, and Newtopia undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/newtopia-and-eastern-health-improve-outcomes-for-individuals-living-with-type-2-diabetes-301675898.html
SOURCE Newtopia Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2022/14/c9140.html
Related Quotes
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
Halozyme's under-the-skin technology helps deliver some of the biggest moneymaking injections, fueling booming growth and prospects for much more. HALO stock is surging.
Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.
Infinity Pharmaceuticals Inc (NASDAQ: INFI) reported an update from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic triple-negative breast cancer (TNBC) patients. Sixty-two patients were enrolled and evaluable for safety, and 57 (were evaluable for efficacy, with a median duration of follow-up of 10.0 months. Encouraging one-year progression-free survival rates in MARIO-3 1L TNBC study regardless of PD-L1 status. 52% increase in one-ye
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Positive Preliminary Results from Combination Therapy of EPI-7386 and Enzalutamide On October 28, 2022, ESSA Pharma Inc (NASDAQ:EPIX) announced multiple poster presentations at the 29th Annual Prostate Cancer Foundation Scientific Retreat, including an update on the Phase 1/2 Study of EPI-7386 in combination with
Biogen had been a sinking ship following its Alzheimer’s flop, but positive results in September have changed the company’s trajectory.
The combination of addiction-drug makers could tap into billions of dollars in settlement and federal funds aimed at expanding access to treatment.
Australian health authorities have recommended against getting a fifth COVID-19 vaccine shot, even as they urged those eligible to sign up for their remaining booster doses as the country's latest COVID wave grows rapidly. Average daily cases had been 47% higher last week than the week before, said Health Minister Mark Butler at a press conference on Tuesday, announcing new vaccination recommendations. Butler said the Australian Technical Advisory Group on Immunisations (ATAGI) had recommended against a fifth dose, or third booster, after evidence from Singapore's recent wave showed that severe illness and death were rare among the vaccinated and that a fifth shot had minimal impact on virus transmission.
‘This technique was developed in the military to allow soldiers to fall asleep at any time,’ says Justin Agustin
A feature on the earphones helps adults with mild-to-moderate hearing loss hear voices better, study shows.
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Commercial Day Highlights Positive Early Launch Metrics for IGALMI™ On October 18, 2022, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) hosted a Commercial Day presentation to provide an update on the recent launch of IGALMI™, which is approved for the acute treatment of agitation associated with schizophrenia or bipolar
Amazon.com Inc. on Tuesday announced the launch of Amazon Clinic, which provides message-based virtual care to get treatments for common medical conditions like allergies, hair loss, and urinary tract infections in 32 states. It will also offer birth control and refills on hypertension drugs, in addition to other prescriptions. It's the latest Amazon venture into the U.S. healthcare system following the acquisitions of PillPack (now called Amazon Pharmacy) in 2018 and direct primary-care provide
The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.
Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.
The faster people are diagnosed, the better the chance that medical intervention can help stave off the progression.
As cannabis users get older and/or as weed consumption among seniors becomes more common (it has quadrupled in the past seven years!) a group of scientists honed in on this large demographic of pot-smoking baby boomers..and guess what? Their results suggest that the use of whole-plant cannabis does not have a negative impact on cognition. In fact, the opposite is true. The study, done at the University of Colorado Boulder, examined the effects of cannabis use in adults aged 60 to 88 with no hist
"Since the day I tried it, I haven’t gone without it!"View Entire Post ›
The company launched Amazon Clinic, the tech giant’s latest effort to expand its healthcare offerings after it closed down its previous telehealth venture.
One woman shared a photo online of a male passenger encroaching on what little space she had on an airplane.
Beets are an earthy root vegetable that come in several varieties including a deep red, a yellow/orange hue, and white sugar beet varieties. The deep red beets are the most popular and are often found raw in the produce section, cooked in the refrigerated packaged goods section, or juiced. The root isn't the only part of the vegetable you can eat; beet greens are also edible and many people cook them down similar to collard greens.No matter the variety, beets have a lot to offer for our health.

source